|本期目录/Table of Contents|

[1]白静,张洁雯,施炜星,等.抗PD-L1 CAR基因的构建及CAR-T的功能活性研究[J].浙江理工大学学报,2017,37-38(自科6):901-908.
 BAI Jing,ZHANG Jiewen,SHI Weixing,et al.Construction of  PD-L1 CAR Gene and Research of Functional Activity of CAR TCells[J].Journal of Zhejiang Sci-Tech University,2017,37-38(自科6):901-908.
点击复制

抗PD-L1 CAR基因的构建及CAR-T的功能活性研究()
分享到:

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第37-38卷
期数:
2017年自科6期
页码:
901-908
栏目:
出版日期:
2017-11-10

文章信息/Info

Title:
Construction of  PD-L1 CAR Gene and Research of Functional Activity of CAR TCells
文章编号:
1673-3851 (2017) 06-0901-08
作者:
白静张洁雯施炜星陈健吕正兵
浙江理工大学,a.生命科学学院;b.浙江省家蚕生物反应器和生物医药重点实验室,杭州 310018
Author(s):
BAI Jing ZHANG Jiewen SHI Weixing CHEN Jian L-Zhengbing
a.College of Life Science; b.Key Laboratory of Silkworm Bioreactor and Biomedicine of  Zhejiang Province, Zhejiang Sci-Tech University, Hangzhou 310018, China
关键词:
肺癌程序性死亡配体嵌合抗原受体单克隆抗体过继细胞治疗
分类号:
Q28
文献标志码:
A
摘要:
鉴于嵌合抗原受体T细胞(chimeric antigen receptor T cells, CAR-T)疗法应用于肿瘤治疗的临床试验已取得很大突破,设计了程序性死亡配体1(programmed death ligand1, PDL1)特异性CAR-T细胞以体外杀伤肺癌细胞。通过克隆表达PDL1(73739),并纯化PDL1蛋白以免疫BALB/c小鼠制备获得PDL1单克隆抗体;克隆PDL1单克隆抗体单链可变区片段,与CD28、41BB、CD3ζ链的基因体外融合构建第三代CAR基因,并克隆于慢病毒载体pCDHCMVEF1copGFP上,包装成慢病毒。该慢病毒感染CD8+T细胞,扩增5 d,测定CAR的表达,表达率可达到22%以上。PD-L1靶向的肿瘤细胞杀伤作用分析显示,抗PDL1 CART细胞有一定的体外杀伤活性。

参考文献/References:

[1] 林城,陈雄,刘静南,等.PD-1/PDL1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展[J].中国肺癌杂志,2014(10):734-740.
[2] COUZIN F J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science,2013,342(6165):1432-1433.
[3] KALOS M, JUNE C H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology[J]. Immunity,2013,39(1):49-60.
[4] ESHHAR Z, WAKS T, GROSS G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and Tcell receptors[J]. Proceedings of the National Academy of Sciences of the United States of America,1993,90(2):720-724.
[5] HEUSER C, HOMBACH A, LOSCH C, et al. Tcell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigenspecific activation of grafted T cells[J]. Gene Therapy,2003,10(17):1408-1419.
[6] LIPOWSKA B G, GILHAM D E, HAWKINS R E, et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges[J]. Cancer Immunology, Immunotherapy: CII,2012,61(7):953-962.
[7] PAK T S, ROSENBERG S A, MORGAN R A. Treating〖JP〗 cancer with genetically engineered T cells[J]. Trends in Biotechnology,2011,29(11):550-557.

相似文献/References:

[1]吴欣欣,李晓艳,武虎,等. 丁酸钠逆转H460/5FU肺癌细胞耐药性的研究[J].浙江理工大学学报,2012,29(04):609.
 WU Xin xin,LI Xiao yan,WU Hu,et al. Study on the Drug Resistance Reversal of Lung Cancer CellsH460/5FU by Sodium Butyrate[J].Journal of Zhejiang Sci-Tech University,2012,29(自科6):609.

备注/Memo

备注/Memo:
收稿日期: 2017-03-03
网络出版日期: 2017-10-10
基金项目: 国家高技术研究发展计划项目(2012ZX09102301009);浙江省自然科学基金项目(13H090015)
作者简介: 白静(1990-),女,河北沧州人,硕士研究生,主要从事细胞免疫疗法方面的研究
通信作者: 吕正兵,E-mail:zhengbingl@126.com
更新日期/Last Update: 2017-11-17